158 filings
Page 4 of 8
8-K
v6zrzyhx
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
3p4 910abg9at
3 Feb 21
Other Events
5:25pm
8-K
shkkbv1w ixk
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
8-K
qrpjug9lfsk4v alx
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
jvplrj439 ebmzbjh
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
cic3y fky6awpe
23 Nov 20
Other Events
12:00am
8-K/A
epv 1mv84
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
rb5v7g6 9b70b1sjfk
9 Nov 20
Other Events
4:02pm
8-K
z4x5y jk1v5xwjtzd1
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K/A
4prl3 zzd6m7j7qbie
5 Oct 20
Submission of Matters to a Vote of Security Holders
4:21pm
8-K
a7uc58
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
865fb6j4
1 Oct 20
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
6a4sn6ourcjf
11 Sep 20
Departure of Directors or Certain Officers
4:17pm
8-K
s5cca meqwc752vl7
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
8-K
35o7capcdlk9 n1yn7h
26 Jun 20
Departure of Directors or Certain Officers
4:06pm
8-K
k24o580y xh
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
pi06nr2z9 3g
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
f46c645p 4qmh
18 Jun 20
Departure of Directors or Certain Officers
4:02pm
8-K
kg8fyta6r
12 Jun 20
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
a6g6 r3vdjot
22 May 20
Departure of Directors or Certain Officers
5:04pm